Global TIGIT Inhibitor Industry – With Acrus Biosciences, Astellas Pharma and AstraZeneca, among others


DUBLIN, 20 December 2021 / PRNewswire / – The “Global TIGIT Inhibitor Drug Opportunity and Clinical Research Overview 2022” the report was added to offer.

The T cell immunoreceptor with Ig and ITIM domains (TIGIT) is one of the most recently identified immune checkpoint inhibitors being evaluated as a potential immunotherapeutic target.

TIGIT is a transmembrane glycoprotein receptor with an Ig-like V-type domain and ITIM in its cytoplasmic domain and is expressed on a wide range of cells, including memory T cells, NK cells, and Tregs. Apart from this, studies have shown high expression of TIGIT on a wide range of solid tumors and hematologic malignancies, making it a potential target in drug development.

Highlights of the Global TIGIT Inhibitor Drug Opportunities Report and Clinical Research Insight 2022:

  • Global TIGIT Inhibitor Market Dynamics
  • Clinical approaches to target TIGIT
  • Role of TIGIT inhibitors in cancer, HIV, autoimmune diseases
  • Number of TIGIT inhibitor drugs in trials
  • TIGIT Inhibitor Trials by Phase, Company, Country, Indication
  • Clinical trial adverse event scenario
  • Company agreement / Partnership / Agreements for ongoing trials
  • Future Outlook of the Global TIGIT Inhibitors Market

Several pharmaceutical companies have developed a strong pipeline of TIGIT inhibitors in their pipeline indicated for the management of several cancers. Ongoing clinical trials are primarily evaluating the role of TIGIT inhibitors in combination with PD-1 / PD-L1 inhibitors or CTLA-4 inhibitors. Combinations of immunotherapy with a double blockade of TIGIT and PD-1 / PD-L1 show promise due to their synergistic enhancement of anti-tumor responses. More recently, Compugen, in collaboration with Bristol Meyer Squibb, is evaluating the triple combination of Opdivo, BMS-986207 (anti-TIGIT) and COM701 (anti-PVRIG). Preliminary data suggests that the triple combination was safe and well tolerated.

Besides cancer, researchers are also evaluating the role of a novel immune checkpoint in other therapeutic conditions, including HIV and autoimmune disorders. TIGIT has been shown to be an attractive target for HIV due to its expression on NK cells and almost all HIV-specific CD8 + T cells. Preclinical studies favored the co-blockade of TIGIT with a PD-1 / PD-L1 inhibitor in HIV patients. The encouraging response from preclinical trials is expected to translate into clinical studies in the years to come. In addition, the researchers also suggested the relationship between Treg cells expressing TIGIT and various autoimmune diseases, including atopic dermatitis, autoimmune thyroiditis, type 1 diabetes, autoimmune uveitis, anemia. aplastic, multiple sclerosis, systemic lupus erythematosus, arthritis and colitis. For now, these studies are mainly limited to in-vivo and preclinical studies.

Currently, the TIGIT inhibitor market is predominantly dominated by therapeutic monoclonal antibodies. Several monoclonal antibodies targeting TIGIT have entered clinical development, including Tiragolumab, Ociperlimab, Vibostolimab, ASP-8374 and COM902. Further improvements in the field of biotechnology and the promising results of the TIGIT inhibitor in combination therapies have led to the development of new bispecific constructs. Currently, a few bispecific antibodies, including AGEN1777, IBI321 and HLX301, have entered the early stages of clinical trials. The emergence of bispecific antibody constructs is expected to show increased efficacy and will reduce the overall cost of therapy and drug development.

Globally, more than 30 ongoing clinical trials are evaluating novel anti-TIGIT antibodies in a wide variety of diseases. Some of the main indications that are expected to give better results by the time these drugs are launched include triple negative breast cancer, non-small cell lung cancer, colorectal cancer, melanoma, gastric cancer, and breast cancer. ‘esophagus. The global market is expected to show positive growth due to the launch of TIGIT therapies in the next few years. Tiragolumab developed by Roche is the leading drug candidate that has received priority review by the US FDA and is expected to hit the market by 2022. The emerging trend of next-generation TIGIT immunotherapies with continued advancements as well that the development of new technologies for the development of targeted therapies gives hope for better therapeutic alternatives in the years to come.

The United States will dominate the development and commercialization landscape for TIGIT inhibitors, which is mainly attributed to the large number of clinical trials underway in the region. In addition, the high concentration of key players in the region who actively invest in research and development will also propel the growth of the market. Alongside the United States, China and South Korea Will also emerge as key markets for TIGIT inhibitor drugs through increased research and development activities.

Main topics covered:

1. Introduction to the TIGIT inhibitor
1.1 Overview
1.2 Historical perspective

2. Role of TIGIT inhibitors in cancer
2.1 Enhanced anti-tumor effects
2.2 Reduced immunosuppressive functions
2.3 Increases anti-tumor immunity

3. Role of TIGIT inhibitors in HIV

4. Role of TIGIT in autoimmune disorders

5. Mechanism of the TIGIT inhibitor

6. Clinical approaches to target TIGIT
6.1 Therapeutic monoclonal antibodies
6.2 Bispecific antibodies
6.3 Small molecule inhibitors

7. FDA Orphan Designation for Tiragolumab

8. Overview of Clinical Trials of Global TIGIT Inhibitors
8.1 By company
8.2 By country
8.3 By patient segment

9. TIGIT Clinical Trials Insight 2022 Global Inhibitors
9.1 Research
9.2 Preclinical
9.3 Phase I
9.4 Phase-I / II
9.5 Phase II
9.6 Phase III

10. Global TIGIT Inhibitor Market Dynamics
10.1 Market drivers
10.2 Marketing challenges

11. Future prospects of the global TIGIT inhibitors market

12. Competitive landscape
12.1 Acrus Biosciences
12.2 Agensus
12.3 Astellas Pharma
12.4 AstraZeneca
12.5 Beige
12.6 Bristol Meyer Squibb
12.7 Compugen
12.8 Sciences of Gilead
12.9 iTeos Therapeutics
12.10 Merck
12.11 Rock
12.12 Seagen
12.13 Seatle genetics
12.14 Shanghai Helnius Biotech

For more information on this report, visit

Media contact:

Research and markets
Laura Wood, senior
[email protected]

For EST office hours, call + 1-917-300-0470
For USA / CAN call toll free + 1-800-526-8630
For GMT office hours, call + 353-1-416-8900

US Fax: 646-607-1907
Fax (outside the United States): + 353-1-481-1716

SOURCE Research and Markets


Back To Top